Condition: aHUS · Atypical Hemolytic Uremic Syndrome · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Bunkyō City, Japan | Not Yet Recruiting |
| Research Site | Hirakata-shi, Japan | Not Yet Recruiting |
| Research Site | Iruma-Gun, Japan | Recruiting |
| Research Site | Kyoto, Japan | Not Yet Recruiting |
| Research Site | Matsumoto-shi, Japan | Not Yet Recruiting |
| Research Site | Miyazaki, Japan | Not Yet Recruiting |
| Research Site | Nagoya, Japan | Recruiting |
| Research Site | Nara, Japan | Not Yet Recruiting |
| Research Site | Nerima-ku, Japan | Not Yet Recruiting |
| Research Site | Sapporo, Japan | Not Yet Recruiting |
| Research Site | Shinjuku-ku, Japan | Not Yet Recruiting |
| Research Site | Tsu, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07308574